Aerie Pharmaceuticals Inc (NASDAQ:AERI)’s Stock Is Sell After More Market Selling

June 17, 2018 - By Mona Holcomb

Investors sentiment decreased to 1.19 in Q1 2018. Its down 0.01, from 1.2 in 2017Q4. It dived, as 18 investors sold Aerie Pharmaceuticals, Inc. shares while 46 reduced holdings. 17 funds opened positions while 59 raised stakes. 39.43 million shares or 13.11% more from 34.86 million shares in 2017Q4 were reported.
Highland Capital L P accumulated 163,300 shares. First Personal Financial Services invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Macquarie Grp Inc Limited reported 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 161,173 were reported by State Bank Of America De. Schwab Charles Inv Mngmt accumulated 182,345 shares. State Of Wisconsin Inv Board has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 2,805 are held by Ameritas Investment Prns. Teacher Retirement System Of Texas holds 6,903 shares or 0% of its portfolio. C Ww Grp Holdings A S invested in 0.06% or 72,739 shares. Geode Mngmt Ltd Com owns 338,677 shares or 0.01% of their US portfolio. Citadel Advsr Limited Liability Com owns 11,161 shares. Proshare Ltd Liability Co holds 0.01% or 21,907 shares. Bnp Paribas Arbitrage holds 0% or 7,379 shares. Invesco Ltd invested in 0.03% or 1.29M shares. Citigroup holds 0% or 39,222 shares in its portfolio.

Since May 21, 2018, it had 2 insider purchases, and 4 selling transactions for $13.13 million activity. The insider Cagle Gerald D. bought 1,000 shares worth $49,450. Kopczynski Casey C. sold 2,708 shares worth $135,806.

The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) registered an increase of 1.87% in short interest. AERI’s total short interest was 5.88 million shares in June as published by FINRA. Its up 1.87% from 5.77M shares, reported previously. With 196,200 shares average volume, it will take short sellers 30 days to cover their AERI’s short positions. The short interest to Aerie Pharmaceuticals Inc’s float is 21.93%.

The stock decreased 0.08% or $0.05 during the last trading session, reaching $64.15. About 287,484 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has declined 8.48% since June 17, 2017 and is downtrending. It has underperformed by 21.05% the S&P500.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.53 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 6 analysts covering Aerie Pharma (NASDAQ:AERI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharma had 11 analyst reports since December 18, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Monday, December 18 by Cantor Fitzgerald. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Friday, February 16 by H.C. Wainwright. The rating was maintained by Canaccord Genuity on Wednesday, January 24 with “Buy”. H.C. Wainwright maintained the shares of AERI in report on Thursday, March 1 with “Buy” rating. Mizuho maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Thursday, March 29 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $7800 target in Wednesday, May 9 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, February 28. Stifel Nicolaus maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Tuesday, January 2 with “Buy” rating. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 8. The firm has “Buy” rating by Mizuho given on Wednesday, May 9.

More important recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Gurufocus.com which released: “Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Sold $9.3 million of Shares” on June 09, 2018, also Streetinsider.com published article titled: “Aerie Pharma (AERI): Early Physician Rhopressa Feedback is Cautiously Positive – Cowen”, Businesswire.com published: “Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference” on May 31, 2018. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) was released by: Businesswire.com and their article: “Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management” with publication date: May 30, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: